Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

Brucellosis Clinical Trial

Official title:

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04301752
• Other study ID #: Mansoura University 13
• Status: Completed
• Start date: February 1, 2019
• Est. completion date: March 1, 2020

Study information

• Verified date: March 2020
• Source: Mansoura University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

Description:

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

The aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have detailed general and neurologic features

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: March 1, 2020
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients >18 years of age with laboratory-confirmed brucellosis

Exclusion Criteria:

• Previous neuropsychiatric disease

Related Conditions & MeSH terms

• Brucellosis
• Cognitive Dysfunction

Intervention

Diagnostic Test:
• MoCA
Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26. Maximum score is 30.

Locations

Country	Name	City	State
Egypt	Mansoura University Hospital	Mansoura

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Eren S, Bayam G, Ergönül O, Celikbas A, Pazvantoglu O, Baykam N, Dokuzoguz B, Dilbaz N. Cognitive and emotional changes in neurobrucellosis. J Infect. 2006 Sep;53(3):184-9. Epub 2006 May 2. — View Citation

Finn TB. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases. 2nd ed. New York: Elsevier, 2004:1665-9.

Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005 Jun 2;352(22):2325-36. Review. — View Citation

Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2921-5.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MoCA s	Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were <26 .	24 hours